- Tumors1000+
- Pathologic Processes1000+
- Nervous System Diseases1000+
- Pathology1000+
- Cancer1000
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Pathologic Processes1000+
- Nervous System Diseases1000+
- Pathology1000+
- Cancer1000
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- PD-L1 positive
- ER positive
- HER2 positive
- EGFR positive
- PR positive
- EGFR negative
- PD-L1 negative
- KRAS positive
- ALK negative
- ER negative
- PR negative
- BRAF positive
- CD20 positive
- BRCA1 positive
- IDH positive
- ALK positive
- BRAF negative
- BRCA2 positive
- ROS1 negative
- HLA positive
- HLA-A positive
- p16 positive
- HR positive
- CD19 positive
- MET positive
- MYC positive
- PIK3CA positive
- RET positive
- ROS1 positive
- TP53 positive
- IDH negative
- dMMR positive
- anti-dsDNA positive
- ANA positive
- MSI-H positive
- BCL2 positive
- KRAS negative
- MET negative
- NF1 positive
- p16 negative
- BCL6 positive
- MSS positive
- NRAS positive
- NTRK positive
- PALB2 positive
- RET negative
- BCR-ABL1 positive
- BRCA1 negative
- HBsAg positive
- HPV negative
- HPV positive
- RAS negative
- RAS positive
- TP53 negative
- anti-Sm positive
- BRCA2 negative
- CFTR positive
- FGFR2 positive
- NTRK negative
- RB1 positive
- ctDNA positive
- pMMR positive
- ABCA4 positive
- CCND1 positive
- Ex19del positive
- HLA negative
- HLA-A negative
- L858R positive
- MDM2 positive
- MGMT negative
- PTEN positive
- RB1 negative
- TTR positive
- BRCA positive
- CD123 positive
- CD5 positive
- CLDN18.2 positive
- COL7A1 positive
- DMD positive
- MGMT positive
- MMR negative
- MSI-H negative
- RF positive
- T790M positive
- TROP2 negative
- TROP2 positive
- dMMR negative
- AKT negative
- APC positive
- APP positive
- C5 positive
- CD30 positive
- DLL3 positive
- EBV positive
- ER/PR positive
- FLT3 positive
- FMR1 positive
- HBB positive
- HBV DNA negative
- HR negative
- HRAS positive
- HbSS positive
- KIT positive
- MMR positive
- NRAS negative
- PSEN1 positive
- PSEN2 positive
- PTCH1 positive
- Ph positive
- Philadelphia chromosome negative
- Philadelphia chromosome positive
- PiZZ positive
- RHO positive
- SMARCA4 positive
- TET2 positive
- p53 positive
- t(11;14) positive
- β-thalassemia positive
- 11q negative
- 11q positive
- AKT positive
- ALPL positive
- ALT positive
- APOL1 positive
- ARID1A positive
- ATM positive
- Anti-PLA2R positive
- Aβ1-42 positive
- B7-H3 positive
- CAG repeat in HTT positive
- CCNE1 positive
- CD23 positive
- CDK4 positive
- CEACAM5 positive
- COL1A1 positive
- COL1A2 positive
- DMPK positive
- Del(17p) negative
- EBV DNA positive
- ER or PR positive
- FGFR2 negative
- FGFR3 positive
- FLT3 negative
- FOLR1 positive
- FOXO1 fusion negative
- FVIII positive
- G719X positive
- GBA positive
- GPC3 positive
- GRN positive
- HBV DNA positive
- HBcAb negative
- HBcAb positive
- HBsAg negative
- HEXA positive
- HEXB positive
- HPV16 positive
- HRD positive
- HbE positive
- IGHV negative
- IGHV positive
- JAK2 positive
- L861Q positive
- LRRK2 positive
- MLH1 positive
- MSH2 positive
- MSH6 positive
- MSS negative
- MTAP negative
- MTAP positive
- MUC1 positive
- MYC negative
- NF2 positive
- NPM1 positive
- NTRK1 positive
- NY-ESO-1 positive
- PDE6A positive
- PDE6B positive
- PIK3CA negative
- PIK3CD positive
- PIK3R1 positive
- PKLR positive
- PMM2 positive
- PMS2 positive
- PSMA positive
- PTEN negative
- RAF positive
- S768I positive
- SMARCB1 negative
- SMN1 positive
- SPINK5 positive
- TTR negative
- UBA1 positive
- UGT1A1 positive
- anti-AChR positive
- anti-MuSK positive
- anti-Ro autoantibodies positive
- anti-Ro/SSA positive
- anti-Smith positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1927nm Fractional Thulium Laser Treatment
- Adjuvant Therapy (except reconstruction)
- Anti-HER2 Therapy
- Anti-Seizure Medications (up to 2 types)
- Any Treatment for Pancreatic Cancer
- At least one prior tumor-directed therapy
- Avoidance of Activities That Cause Joint Pain
- Beovu
- Biologic Anti-Neoplastic Agent
- Branch Retinal Vein Occlusion (BRVO)
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
7734 trials
Kingman, KS (<20 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test a combination of drugs to see if they are effective in reducing the chance of cancer recurrence or developing new cancers.
Efficacy & Safety Awards
Pivotal Trial
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a 4-drug combo vs. a 3-drug combo to see if the former is more effective in shrinking cancer or preventing its return.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing if vitamin D3 along with regular cancer drugs and another drug that helps the immune system can better treat colorectal cancer that has spread. Vitamin D3 may help the body use essential minerals, making the cancer drugs more effective. Vitamin D3 has been shown to slow down cancer cell growth and help them mature, and it has been effective in reducing intestinal tumors in animal studies.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is comparing radiation therapy alone to radiation therapy with lymph node dissection in treating breast cancer patients who have already had chemotherapy and surgery.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Recruiting
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial studies four drugs to treat patients with worsening meningioma. These drugs work by blocking enzymes that the tumor cells need to grow. The trial focuses on patients whose tumors have specific genetic mutations.
Efficacy & Safety Awards
No Placebo-Only Group
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares shorter chemo-immunotherapy without anthracyclines to usual chemo-immunotherapy to treat early-stage triple negative breast cancer. Drugs used to stop cancer cells from growing/dividing & kill them, plus an immunotherapy drug.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests a combination of two drugs to see if they're better than one drug at preventing breast cancer from coming back in patients with high risk, HER2 positive breast cancer.
Efficacy & Safety Awards
Pivotal Trial
Get notified when new Breast Cancer trials are postedWe'll send you an email whenever new trials are posted
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Waitlist
Phase 2 & 3
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Recruiting
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test new targeted cancer therapies against standard of care therapy in order to find more effective treatments.
Efficacy & Safety Awards
No Placebo-Only Group
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing if rituximab works better with or without stem cell transplant for mantle cell lymphoma in patients who are in first complete remission.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing two different chemotherapy combinations to treat triple negative breast cancer to see which is more effective.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 33 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is comparing two types of chemotherapy drugs to see which is more effective in treating patients with residual triple negative basal-like breast cancer.
Efficacy & Safety Awards
Approved for 10 Other Conditions
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Recruiting
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying nivolumab and ipilimumab to see how well they work with or without sargramostim in treating patients with stage III-IV melanoma that cannot be removed by surgery.
Efficacy & Safety Awards
No Placebo-Only Group
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing two different treatments for melanoma that cannot be removed by surgery. The first treatment is immunotherapy with monoclonal antibodies, followed by targeted therapy with dabrafenib and trametinib. The second treatment is targeted therapy with dabrafenib and trametinib, followed by immunotherapy with monoclonal antibodies. It is not yet known which treatment is more effective.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial studies crizotinib for patients with stage IB-IIIA NSCLC who have had surgery and have an ALK fusion mutation. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Get notified when new Hypertriglyceridemia trials are postedWe'll send you an email whenever new trials are posted
Wichita, KS (<50 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a medication called Pegozafermin to see if it can lower high levels of fats in the blood in people with severe hypertriglyceridemia. These patients have very high triglyceride levels, which can lead to serious health issues. The medication aims to reduce these fat levels to improve their health.
Efficacy & Safety Awards
Pivotal Trial
Wichita, KS (<50 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test if ubrogepant is safe and effective for young people with migraines. Ubrogepant is a medication taken by mouth to treat migraine headaches. It works by blocking a protein in the brain that causes migraine pain. The study focuses on children and adolescents who suffer from migraines.
Efficacy & Safety Awards
Pivotal Trial
1
2
3
…50